🇺🇸 FDA

Company profile · Sponsor

Aptose

Aptose Biosciences

APTOF · NYSE biotech TORONTO, USA
Pipeline
8
Drugs
0
Patents
7

Quick answer

Aptose (APTOF) is a biotech company. headquartered in TORONTO, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 7 patents to this profile..

Company facts

Ticker APTOF
Exchange NYSE
Company type biotech
Headquarters TORONTO, USA
SEC CIK 0000882361

Pipeline (8)

Search pipeline →

  1. Virulizin®

    Aptose

    Pancreatic Cancer

    phase 3 small molecule completed

    1 trial

  2. GTI-2040

    Aptose

    Carcinoma, Renal Cell

    phase 2 small molecule completed

    1 trial

  3. GTI-2040

    Aptose

    Acute Myeloid Leukemia

    phase 2 mab completed

    1 trial

  4. Tuspetinib

    Aptose

    Leukemia, Myeloid, Acute

    phase 2 small molecule active

    1 trial

  5. APTO-253

    Aptose

    Acute Myelogenous Leukemia in Relapse

    phase 1 small molecule terminated

    1 trial

  6. CG-806

    Aptose

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

  7. CG-806

    Aptose

    Chronic Lymphocytic Leukemia

    phase 1 small molecule terminated

    1 trial

  8. LOR-253 HCl

    Aptose

    Advanced or Metastatic Solid Tumours

    phase 1 small molecule completed

    1 trial

Patents (7)

Search patents →

  1. US 11279703

    Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof

    Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11149047

    Aryl imidazoles for treatment of cancer

    Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11104957

    Compositions and methods for treating cancers

    Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10080739

    Aryl imidazoles and their use as anti-cancer agents

    Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9567643

    Compositions and methods for treating cancers

    Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8987305

    2,4,5-trisubstituted imidazoles and their use as anti-microbial agents

    Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8969372

    Aryl imidazoles and their use as anti-cancer agents

    Expires Mon Feb 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Aptose?

Aptose (APTOF) is a biotech company. headquartered in TORONTO, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 7 patents to this profile..

What pipeline programs does Aptose sponsor?

We track 8 ClinicalTrials.gov-linked programs for Aptose, including Virulizin® and 7 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Aptose company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.